SAN FRANCISCO--(BUSINESS WIRE)--Jun. 3, 2015--
Jaguar Animal Health, Inc. (NASDAQ:JAGX), an animal health company
focused on developing and commercializing first-in-class
gastrointestinal products for companion and production animals,
announced today that it has named Folkert Kamphuis to its board of
directors. This appointment deepens Jaguar’s global animal health
business development, strategic planning and commercialization expertise
as the company focuses on its post-IPO clinical and corporate milestones.
Mr. Kamphuis most recently served as Global Head of Strategic Planning
at Novartis Animal Health, the former animal health unit of Swiss
pharmaceutical giant Novartis, a role in which he oversaw business
development and licensing, portfolio and salesforce development, and was
a member of Novartis’s Animal Health Executive Committee. He joined
Novartis Animal Health in 2009, and from 2012 to 2014 served as General
Manager North America. Prior to 2009, Mr. Kamphuis spent 20 years in
various executive, business development and global marketing roles at
Pfizer Animal Health/Pharmacia and Merial.
“We conducted an exhaustive search for someone who would further
strengthen our board’s breadth of talent and background, and we are
delighted to have identified a global animal health pioneer of Folkert’s
stature,” commented Jaguar CEO Lisa Conte. “I’m confident that Folkert’s
broad experience and deep industry knowledge will prove highly
beneficial as we work to build Jaguar into a global leader in the field
of companion and production animal gastrointestinal health.”
“Jaguar’s team is building on their past success in the development of
first-in-class anti-secretory gastrointestinal treatments for humans to
formulate and commercialize a broad-based suite of products that address
unmet needs in companion and production animal health throughout the
world,” stated Mr. Kamphuis, “and I am thrilled to be part of the team.”
About Jaguar Animal Health, Inc.
Jaguar Animal Health, Inc. is an animal health company focused on
developing and commercializing first-in-class gastrointestinal products
for companion and production animals. Canalevia™ is Jaguar’s
lead prescription drug product candidate for the treatment of various
forms of watery diarrhea in dogs. Neonorm™ Calf is the
company’s lead non-prescription product. Canalevia is a canine-specific
formulation of crofelemer, an active pharmaceutical ingredient isolated
and purified from the Croton lechleri tree, which is sustainably
harvested. Neonorm is a standardized botanical extract derived from the Croton
lechleri tree. Canalevia and Neonorm are distinct products that act
at the same last step in a physiological pathway generally present in
mammals. Jaguar has filed nine Investigational New Animal Drug
applications, or INADs, with the FDA and intends to develop
species-specific formulations of Neonorm in six additional target
species, and formulations of Canalevia for cats, horses and dogs.
For more information, please visit www.jaguaranimalhealth.com.
Jaguar-JAGX
View source version on businesswire.com: http://www.businesswire.com/news/home/20150603005442/en/
Source: Jaguar Animal Health, Inc.
Jaguar Animal Health
Peter Hodge, 203-539-0423
phodge@jaguaranimalhealth.com
